Author

Xuanlin Liu

Leiden UniversityORCID 0009-0008-2017-4696Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Anne‐Grete MärtsoniD· 2 shared J. G. Coen van HasseltiD· 2 shared Ashley N. BrowniD· 1 shared Dirk-Jan van den Berg· 1 shared Evelyn J. Franco· 1 shared Jérémie GuedjiD· 1 shared Jorn Brink· 1 shared Kaley C. Hanrahan· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Anne‐Grete MärtsonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Novel Hollow Fiber Infection Model (HFIM) for Antiviral PK/PD studies of CMV infection.

Lalitya M. Sudarsono, Suzanne A M Wenker, Xuanlin Liu, Jorn Brink, Dirk-Jan van den Berg, J. G. Coen van Hasselt, Anne‐Grete Märtson

This paper introduces a novel hollow fiber infection model (HFIM) for PK/PD studies of ganciclovir in CMV infection, enabling reliable drug exposure and viral dynamics analysis.

Antimicrobial Agents and Chemotherapy · Jun 18, 2026Peer-reviewedPharmacology & Toxicology

Late treatment initiation leads to reduced antiviral potency

Xuanlin Liu, Evelyn J. Franco, Sean N. Avedissian, Kaley C. Hanrahan, Jérémie Guedj, J. G. Coen van Hasselt, Ashley N. Brown, Anne‐Grete Märtson

This study shows that late antiviral treatment initiation reduces drug potency (EC50), and a time-varying EC50 model better fits viral load data than a constant EC50 model.

bioRxiv · Sep 24, 2025 · PreprintPharmacology & Toxicology